1-(3-aminophenyl)-6-(3-hydroxyphenyl)-2-naphthol | 1064680-92-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 1-(3-aminophenyl)-6-(3-hydroxyphenyl)-2-naphthol
• 英文别名: 1-(3-aminophenyl)-6-(3-hydroxyphenyl)naphthalen-2-ol
• CAS: 1064680-92-7
• 化学式: C₂₂H₁₇NO₂
• 分子量: 327.382
• InChiKey: DMEBSJDKEXDYPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-aminophenyl)-6-(3-hydroxyphenyl)-2-naphthol 、 3-硝基苯磺酰氯 在 polystyrene supported morpholine 、 polystyrene supported dimethylaminopyridine 作用下， 以 四氢呋喃 为溶剂， 反应 30.0h， 生成 N-(3-(2-hydroxy-6-(3-hydroxyphenyl)naphthalen-1-yl)phenyl)-3-nitrobenzenesulfonamide
  参考文献：
  名称：

  Lead Optimization of 17β-HSD1 Inhibitors of the (Hydroxyphenyl)naphthol Sulfonamide Type for the Treatment of Endometriosis

  摘要：

  The reduction of estrone to estradiol, the most potent estrogen in human, is catalyzed by 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1). A promising approach for the treatment of estrogen-dependent diseases is the reduction of intracellular estradiol formation by inhibition of 17 beta-HSD1. For the species-specific optimization of the (hydroxyphenyl)naphthols, a combinatorial approach was applied and enhanced by a focused synthesis that resulted in the aromatic-substituted (hydroxyphenyl)naphthol sulfonamides. Rigidification of 12 led to the 4-indolylsulfonamide 30, which is a highly active and selective human 17 beta-HSD1 inhibitor, as well as a highly potent and selective inhibitor of 17 beta-HSD1 from Callithrix jacchus. It shows no affinity to the estrogen receptors a and 9 and good intracellular activity (T47D). Thus, compound 30 shows good properties for further ADMET studies and might be a candidate for the in vivo proof of concept in C. jacchus.

  DOI：

  10.1021/jm201735j
• 作为产物：
  描述：

  1,6-二溴-2-甲氧基萘 在 四(三苯基膦)钯 、 三溴化硼 、 sodium carbonate 、 caesium carbonate 作用下， 以 甲醇 、 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， -78.0~150.0 ℃ 、150.0 kPa 条件下， 反应 36.25h， 生成 1-(3-aminophenyl)-6-(3-hydroxyphenyl)-2-naphthol
  参考文献：
  名称：

  Lead Optimization of 17β-HSD1 Inhibitors of the (Hydroxyphenyl)naphthol Sulfonamide Type for the Treatment of Endometriosis

  摘要：

  The reduction of estrone to estradiol, the most potent estrogen in human, is catalyzed by 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1). A promising approach for the treatment of estrogen-dependent diseases is the reduction of intracellular estradiol formation by inhibition of 17 beta-HSD1. For the species-specific optimization of the (hydroxyphenyl)naphthols, a combinatorial approach was applied and enhanced by a focused synthesis that resulted in the aromatic-substituted (hydroxyphenyl)naphthol sulfonamides. Rigidification of 12 led to the 4-indolylsulfonamide 30, which is a highly active and selective human 17 beta-HSD1 inhibitor, as well as a highly potent and selective inhibitor of 17 beta-HSD1 from Callithrix jacchus. It shows no affinity to the estrogen receptors a and 9 and good intracellular activity (T47D). Thus, compound 30 shows good properties for further ADMET studies and might be a candidate for the in vivo proof of concept in C. jacchus.

  DOI：

  10.1021/jm201735j

文献信息

• 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases
  申请人：Hartmann Rolf

  公开号：US20100204234A1

  公开（公告）日：2010-08-12

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂以及生产方法。
• 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases
  申请人：Hartmann Rolf

  公开号：US08546392B2

  公开（公告）日：2013-10-01

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂及其生产方法。
• New Drug-Like Hydroxyphenylnaphthol Steroidomimetics As Potent and Selective 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Estrogen-Dependent Diseases
  作者：Sandrine Marchais-Oberwinkler、Marie Wetzel、Erika Ziegler、Patricia Kruchten、Ruth Werth、Claudia Henn、Rolf W. Hartmann、Martin Frotscher

  DOI：10.1021/jm1009082

  日期：2011.1.27

  Inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) is a novel and attractive approach to reduce the local levels of the active estrogen 17 beta-estradiol in patients with estrogen-dependent diseases like breast cancer or endometriosis. With the aim of optimizing the biological profile of 17 beta-HSD1 inhibitors from the hydroxyphenylnaphthol class, structural optimizations were performed at the 1-position of the naphthalene by introduction of different heteroaromatic rings as well as substituted phenyl groups. In the latter class of compounds, which were synthesized applying Suzuki-cross coupling, the 3-methane-sulfonamide 15 turned out to be a highly potent 17 beta-HSD1 inhibitor (IC50 = 15 nM in a cell-free assay). It was also very active in the cellular assay (T47D cells, IC50 = 71 nM) and selective toward 17 beta-HSD2 and the estrogen receptors alpha and beta. It showed a good membrane permeation and metabolic stability and was orally available in the rat.
• 17BETA-HYDROXYSTEROID-DEHYDROGENASE-TYP1-INHIBITOREN ZUR BEHANDLUNG HORMONABHÄNGIGER ERKRANKUNGEN
  申请人：Universität des Saarlandes

  公开号：EP2131826A2

  公开（公告）日：2009-12-16
• US8546392B2
  申请人：——

  公开号：US8546392B2

  公开（公告）日：2013-10-01